Amit Rakhit, Md, Mba: Developing Therapies For Fragile X Syndrome

Amit Rakhit, MD, MBA: Developing Therapies for Fragile X Syndrome

Amit Rakhit, MD, MBA: Measuring Improvement in Fragile X Syndrome, Other Rare Conditions

Amit Rakhit, MD: Ovid Therapeutics' Approach

How Ovid Therapeutics Works With Patient Groups

Fragile X Syndrome Overview

Testing Angelman and Fragile X Syndrome Therapies in Younger Patients

2019 FAST Summit on Angelman Syndrome - OV101 for the Treatment of AS, Dr. Amit Rhakit, Ovid

FAST

An Innovative Therapeutic Strategy for Fragile X Syndrome

FRAXA Research Foundation

Advances in Targeted Treatments in Fragile X Syndrome and Autism

University of California Television (UCTV)

Encouraging pharma and biotech scientists to focus their resources on Fragile X

FRAXA Research Foundation

Zynerba CBD Gel Clinical Trial for Fragile X Overview

FRAXA Research Foundation

Ovid Therapeutics – OV101 Clinical Trial

FAST

Fragile X Syndrome - A Cause and Cure? (3 of 9)

DNA Learning Center

Drug Development Requires Patients’ Input To Know What is Important

Synaptic Defects and Targeted Treatments in Fragile X Syndrome - Elizabeth Berry-Kravis, MD, PhD

RTI International

The Search for Fragile X Cure - Cheddar

FRAXA Research Foundation

Bev Sher on Speech and Language Interventions in Fragile X syndrome (Nov 2019)

Fragile X Association of Australia

Medication for Individuals with Fragile X Syndrome

National Fragile X Foundation

Tetra’s Fragile X Clinical Trial - The Most Successful So Far

FRAXA Research Foundation

Ovid Therapeutics: Focusing on Rare Neurologic Diseases